06/28/2016 – Gilead Sciences, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. Gilead Sciences has a 52-week low of $77.92 and a 52-week high of $120.37. The daily volume was measured at 7.37 million shares. Analysts expect the variance to be within $11.6 of the average price. The stock was sold at an average price of $87.82, for a total transaction of $8,782,000.00. The current price escalated 2.63% from its SMA 50 of $84.66. Citigroup Inc. restated a “buy” rating and issued a $110.00 price objective on shares of Gilead Sciences in a report on Monday, March 28th. Following the sale, the chief executive officer now owns 1,170,963 shares in the company, valued at $102,705,164.73. The company has an Average Rating of 2.08 based on analysts tracked by Thomson Reuters. The stock has a market capitalization of $114.36B and it has 1.33B outstanding shares. “Underperform” verdict was shared by 0 analyst and “Overweight” recommendation was issued by 5 analyst.
Advertisement
Several research analysts recently commented on the stock.
Gilead Sciences, Inc. had its “hold” rating reiterated by analysts at Maxim Group. The total 732.68 thousand shares were bought and sold throughout the most recent trading session more than average volume of 680.69 thousand shares.
At the end of the annual period ended 2015-12-31, the company had 1422 common shares. (NASDAQ:GILD) inched down -0.79% to finish at $86.55 in previous trading session. The webcast will be archived on www.gilead.com for one year. The stock now has Price to Sales (P/S) value of 3.65 where Price to Book (P/B) value stands at 8.93.GILD is now showing ROA (Return on Assets) value of 36.6% where ROE (Return on Equity) is 105.7%. The fund owned 545,544 shares of the biopharmaceutical company’s stock after selling 67,429 shares during the period. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $104.96 price objective for the company.in a report on Monday, April 4th. The highest target price given by the Brokerage Firm to the stock is $135 and the lowest target is $97 for the short term.
Advertisement
05/26/2016 – Gilead Sciences, Inc. had its “equal-weight” rating reiterated by analysts at Morgan Stanley.
